A LinkedIn post from Neuromod Devices Ltd highlights the company’s presence at the Australian College of Audiology incorporating HAASA’s ACAud event in Gold Coast, Australia. The post notes that Neuromod representative Andrew Coulter is engaging with attendees at Booth 31.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post references data from The Medical Journal of Australia indicating that 33% of Australians have experienced tinnitus in their lifetime and 17% report constant noise. Neuromod’s Lenire device is described as having demonstrated significant tinnitus relief across three large-scale clinical trials and in real‑world patients.
By emphasizing home‑based use and “proven” outcomes, the post suggests Neuromod is targeting both clinical adoption and patient convenience in a sizeable national market. For investors, this outreach to audiologists and ENT professionals may signal efforts to deepen clinician relationships, potentially supporting future revenue growth and reinforcing the company’s positioning within the tinnitus treatment segment.